Amneal Pharmaceuticals, Inc.
AMRXBusiness Summary
Amneal Pharmaceuticals, Inc. is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines 1. The company operates principally in the United States, India, and Ireland 2. Its core business model revolves around three reportable segments: Affordable Medicines, Specialty, and AvKARE 3. The company generates revenue by supplying finished pharmaceutical products to customers, including major wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and other pharmaceutical companies 4. Revenue is recognized when control of products is transferred to customers, typically upon shipment or delivery 5. The company also enters into licensing arrangements for intellectual property (IP) rights and provides research and development (R&D) and contract manufacturing services 6.
The Affordable Medicines segment includes over 280 product families in the United States, covering a wide range of dosage forms and delivery systems such as oral solids, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals 7. This segment focuses on developing products with substantial barriers-to-entry due to complex formulations, manufacturing, or legal/regulatory challenges, aiming for first-to-file (FTF), first-to-market (FTM), and other high-value products 8. As of December 31, 2025, the Affordable Medicines segment had 61 products with a pending Abbreviated New Drug Application (ANDA) and 43 products in various stages of development, with 95% being non-oral solid products 9. In 2025, products manufactured in U.S. facilities contributed 46% of Affordable Medicines product net revenue, while those manufactured in India contributed 24% 10. Approximately 30% of Affordable Medicines net revenue for the year ended December 31, 2025, was supplied by third-party manufacturers 11. Key developments in 2025 included tentative FDA approval for beclomethasone dipropionate HFA inhalation aerosol (generic QVAR®) and FDA approval for albuterol sulfate inhalation aerosol (generic ProAir® HFA), both manufactured in the Ireland facility 12. The company also received FDA approval for two denosumab biosimilars, Boncresa™ and Oziltus™, in December 2025, bringing its total commercially available biosimilars in the U.S. to five 13.
The Specialty segment is dedicated to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products, primarily targeting central nervous system disorders, including Parkinson's disease, and endocrine disorders 14. Significant products in this segment include CREXONT® (combination of carbidopa and levodopa extended release capsules), RYTARY® (extended release oral capsule formulation of carbidopa-levodopa), UNITHROID® (levothyroxine sodium), and Brekiya® (dihydroergotamine mesylate) injection 15. Brekiya® autoinjector, approved by the FDA in May 2025, was launched in the U.S. in October 2025 16. In 2025, an authorized generic version of RYTARY® was launched 17. CREXONT® expanded its U.S. insurance coverage from approximately 30% of covered lives at the end of 2024 to over 50% at the end of 2025 18.
The AvKARE segment distributes pharmaceuticals primarily to governmental agencies, with a focus on the U.S. Department of Defense and the U.S. Department of Veterans Affairs 19. AvKARE also re-packages bottle and unit dose pharmaceuticals and vitamins under the names AvKARE and AvPAK, and acts as a wholesale distributor of pharmaceuticals, over-the-counter drugs, and medical supplies to retail and institutional customers across the U.S., particularly those serving low-income and uninsured patients 20. Operating results for the sale of Amneal products by AvKARE are included in the Affordable Medicines segment 21.
For the year ended December 31, 2025, total net revenue increased by 8.0% to $3.018 billion 22 from $2.793 billion in the prior year 23. Cost of goods sold increased by 7.4% to $1.905 billion 24 from $1.773 billion 25. Gross profit rose to $1.113 billion 26 from $1.020 billion 27, with gross margin increasing to 36.9% 28 from 36.5% 29. Selling, general and administrative (SG&A) expenses increased by 10.6% to $526.8 million 30 from $476.4 million 31. Research and development (R&D) expenses decreased by 2.4% to $186.2 million 32 from $190.7 million 33. Operating income increased by 58.1% to $394.1 million 34 from $249.3 million 35. Net income was $127.9 million 36 compared to a net loss of $73.9 million in the prior year 37. Diluted EPS was $0.22 38 compared to $(0.38) in the prior year 39. Cash and cash equivalents were $282.0 million 40 as of December 31, 2025, up from $110.6 million 41 in the prior year. Total indebtedness was $2.7 billion 42, comprising $2.1 billion 43 in Term Loan Due 2032 and $600.0 million 44 in Senior Notes Due 2032. Free cash flow is not explicitly stated, but net cash provided by operating activities was $339.992 million 45.
Year-over-year, Affordable Medicines net revenue increased by 3.6% to $1.745 billion 46, driven by $122.6 million 47 in new product launches and strong volume growth, partially offset by price erosion 48. Specialty net revenue increased by 18.6% to $528.5 million 49, primarily due to increases of $58.1 million 50 from CREXONT® and $23.7 million 51 from UNITHROID®, partially offset by a $6.0 million 52 decrease in IPX203 out-licensing revenue 53. AvKARE net revenue increased by 12.3% to $744.7 million 54, driven by growth in the government label channel from new product introductions, partially offset by a decline in the lower margin distribution channel 55. Affordable Medicines gross profit as a percentage of net revenue decreased to 39.2% 56 from 40.0% 57, while Specialty gross profit as a percentage of net revenue decreased to 53.5% 58 from 54.5% 59. AvKARE gross profit as a percentage of net revenue increased to 19.7% 60 from 15.6% 61.
Significant operational developments in 2025 included the FDA approval and U.S. launch of Brekiya® autoinjector in October 62, and the FDA approvals of Boncresa™ and Oziltus™ denosumab biosimilars in December 63. The company also received tentative FDA approval for generic QVAR® and FDA approval for generic ProAir® HFA, marking the first commercial approvals for products manufactured in its Ireland facility 64. In December 2025, the company entered into a distribution agreement with Valorum Oncology, LLC for ALYMSYS® 65. In September 2025, a Biologics License Application (BLA) was submitted to the FDA for the omalizumab biosimilar candidate 66. The company also began a multi-year enterprise resource planning (ERP) system implementation for certain parts of its business 67.
Business Outlook
For the upcoming period, the company expects to make $21.0 million 68 in principal payments on the Term Loan Due 2032 during 2026, with no principal due on the Senior Notes Due 2032 until maturity 69. Interest payments totaling $193.9 million 70, excluding the impact of the interest rate swap, are expected during 2026 related to the Term Loan Due 2032 and Senior Notes Due 2032 71. The company anticipates investing approximately $110.0 million 72 during 2026 for capital expenditures to support and grow existing operations, primarily for manufacturing equipment, IT, and facilities, net of expected contributions from Metsera, Inc. 73.
A major growth area for the company is its injectable portfolio, with R&D prioritizing new product innovations such as drug/device combinations, peptides, long-acting injectables, and large volume parenteral bags 74. The company has expanded its manufacturing capabilities and infrastructure to support this expanding business, focusing on development, commercialization, and scaling a differentiated injectables portfolio 75. The strategic collaboration agreement with ApiJect Systems, Corp., entered into on May 8, 2025, is a 15-year agreement where the company will install and operate manufacturing equipment leased from ApiJect at its Brookhaven, New York facility to support production of ApiJect’s proprietary blow fill seal (BFS) delivery systems and the company's growing injectable portfolio 76. The company will pay a low-digit royalty to ApiJect for commercial products manufactured using this equipment and has the right to purchase the equipment for a nominal amount at the end of the term 77. The collaboration also includes development of additional injectable product programs utilizing ApiJect’s BFS platform, for which the company is entitled to receive consideration for development work 78.
Another significant growth vector is the biosimilar portfolio. The company received FDA approval for two denosumab biosimilars, Boncresa™ and Oziltus™, in December 2025, reinforcing its position in this fast-growing category and underscoring biosimilars as a key long-term growth driver within the Affordable Medicines segment 79. These products were developed by mAbxience S.L. 80. In September 2025, the company submitted a BLA to the FDA for its omalizumab biosimilar candidate 81. The collaboration agreement with Metsera, Inc., entered into on September 30, 2024, designates the company as Metsera’s preferred global supply partner for its portfolio of weight loss medicines and grants an exclusive license to commercialize certain Metsera products in select emerging markets, including India, certain Southeast Asian countries, Africa, and the Middle East 82. The company is constructing two manufacturing facilities in India for API production and fill-finish manufacturing, with Metsera funding an agreed-upon percentage of these costs, up to $100 million 83. Following Pfizer's acquisition of Metsera and exercise of a change-in-control provision on January 30, 2026, the agreement's term was shortened from seven to four years from the date of first commercial sale, eliminating the company's rebate and construction cost reimbursement obligations, while Metsera's cost sharing commitment of up to $100 million 84 remains unchanged 85.
The company does not expect a material impact related to inflation for the year ending December 31, 2026 86. However, rising inflationary pressures due to higher input costs, including higher material, transportation, labor, and other costs, could exceed expectations and adversely impact operating results in future periods 87. The company is closely monitoring tariff and trade developments and will take actions to reduce or minimize any material negative impact 88.
Planned capital allocation for 2026 includes approximately $110.0 million 89 for capital expenditures, primarily for investments in manufacturing equipment, IT, and facilities, net of expected contributions from Metsera, Inc. 90. The company’s current policy is to retain all earnings, if any, for use in business operations or to reduce debt, and it has no present plans to pay cash dividends on common stock in the foreseeable future 91.
The company is subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments 92. On February 1, 2025, the Administration imposed a 10% tariff on all products from China under the International Emergency Economic Powers Act (IEEPA) 93, though this was invalidated by a Supreme Court ruling on February 20, 2026 94. On April 14, 2025, the Department of Commerce Bureau of Industry and Security (DOCBIS) initiated a Section 232 investigation into the effects on national security of pharmaceutical imports, including whether tariffs should be imposed 95. A separate Section 232 investigation was initiated on September 26, 2025, for imports of personal protective equipment, medical consumables, and medical equipment 96. On February 20, 2026, President Trump imposed a 10% global tariff for 150 days under Section 122 of the Trade Act of 1974, with FDF and API exempt as of the filing date 97. The recently enacted One Big Beautiful Bill Act (OBBBA) on July 4, 2025, introduces significant changes to U.S. healthcare programs, including Medicaid, Medicare, and Affordable Care Act marketplaces, which may reduce federal healthcare spending, alter eligibility requirements, and potentially lead to lower prescription volumes and decreased demand for products 98. OBBBA also includes provisions that may increase compliance obligations and administrative complexity for manufacturers participating in government programs 99.
Risk Factors
The company faces intense competition in the pharmaceutical industry from both brand and generic drug product companies, which could significantly limit growth and materially adversely affect financial results 100. The illegal distribution and sale of counterfeit or stolen products by third parties could negatively impact the company's reputation and financial condition 101. The company's business is highly dependent on market perceptions of its safety and quality, and adverse events or public criticism of drug pricing could cause sales to decline 102. A substantial portion of total revenues is derived from sales of a limited number of products, making the company vulnerable to market conditions and regulatory actions affecting these products 103. Manufacturing or quality control problems, such as the Warning Letter issued by the FDA to its Gujarat, India facility in August 2025, may damage the company's reputation, demand costly remedial activities, and negatively impact business 104. The company's profitability depends on major customers, with the four largest accounting for approximately 71% 105 of consolidated net revenue for the year ended December 31, 2025, and the loss of any one could materially affect operating results 106. Supply chain disruptions, including reliance on single suppliers for raw materials and geopolitical events like the Red Sea attacks or tensions between China and Taiwan, could have a material adverse effect 107. Changes in trade policy, including the imposition of tariffs, may increase costs, affect product availability, and disrupt supply chains 108. A U.S. government shutdown could adversely impact regulatory, operational, and financial performance due to delays in FDA and DEA interactions and interruptions in government contracting for the AvKARE segment 109. The company has a substantial amount of indebtedness, totaling $2.7 billion 110 as of December 31, 2025, which could increase vulnerability to adverse economic conditions and limit financial flexibility 111. Obligations under a tax receivable agreement (TRA) may be substantial, with an unrecorded contingent TRA liability of $129.1 million 112 as of December 31, 2025, which could significantly impact future results if realized 113. The Amneal Group controls approximately 48% 114 of the voting power of outstanding Class A Common Stock, potentially leading to conflicts of interest with other stockholders 115. The company's international operations in India and Ireland, and potential expansion into new geographies, expose it to increased regulatory, economic, social, and political uncertainties 116. Global economic conditions, including inflation and efforts to contain healthcare costs, could harm the business 117. The recently enacted One Big Beautiful Bill Act (OBBBA) in July 2025 may reduce future Medicare reimbursement rates and Medicaid participation, potentially decreasing demand for products and increasing compliance costs 118.
Management Priorities
Management's message to shareholders emphasizes the company's position as a diversified, global biopharmaceutical company focused on essential medicines across its Affordable Medicines, Specialty, and AvKARE segments. They highlight the strategic importance of new product launches and pipeline development, particularly in complex generics, injectables, and biosimilars, as well as branded products for central nervous system and endocrine disorders. Management notes the growth in the Specialty segment, with CREXONT® expanding U.S. insurance coverage to over 50% 119 of covered lives by the end of 2025, and the launch of Brekiya® autoinjector in October 2025 120. The company also achieved significant regulatory milestones in 2025, including FDA approvals for generic QVAR® and generic ProAir® HFA from its Ireland facility, and the approval of two denosumab biosimilars, Boncresa™ and Oziltus™ 121. For the upcoming year, management expects to make $21.0 million 122 in principal payments on the Term Loan Due 2032 and $193.9 million 123 in interest payments, excluding the interest rate swap impact, during 2026 124. They plan to invest approximately $110.0 million 125 in capital expenditures for 2026, net of Metsera, Inc. contributions 126. Strategic priorities include continued investment in R&D for high-value products, expanding manufacturing capabilities for injectables and biosimilars, and leveraging strategic collaborations like those with ApiJect and Metsera to drive future growth. Management also acknowledges the potential impacts of the One Big Beautiful Bill Act (OBBBA) and ongoing trade policy developments, while stating no material impact from inflation is expected for 2026 127.
View Source Annual Report on SEC.gov ↗
References
- [1] Item 1, Business — Overview
- [2] Item 1, Business — Overview
- [3] Item 1, Business — Segments of the Business
- [4] Item 3, Revenue Recognition — Pharmaceutical Product Sales Performance Obligations
- [5] Item 3, Revenue Recognition — Pharmaceutical Product Sales Performance Obligations
- [6] Item 3, Revenue Recognition — Revenue Recognition
- [7] Item 1, Business — Affordable Medicines
- [8] Item 1, Business — Affordable Medicines
- [9] Item 1, Business — Affordable Medicines
- [10] Item 1, Business — Manufacturing and Distribution
- [11] Item 1, Business — Manufacturing and Distribution
- [12] Item 1, Business — Affordable Medicines
- [13] Item 1, Business — Affordable Medicines
- [14] Item 1, Business — Specialty
- [15] Item 1, Business — Specialty
- [16] Item 1, Business — Specialty
- [17] Item 7, MD&A — Specialty
- [18] Item 7, MD&A — Specialty
- [19] Item 1, Business — AvKARE
- [20] Item 1, Business — AvKARE
- [21] Item 1, Business — AvKARE
- [22] Item 7, MD&A — Consolidated Results
- [23] Item 7, MD&A — Consolidated Results
- [24] Item 7, MD&A — Consolidated Results
- [25] Item 7, MD&A — Consolidated Results
- [26] Item 7, MD&A — Consolidated Results
- [27] Item 7, MD&A — Consolidated Results
- [28] Item 7, MD&A — Consolidated Results
- [29] Item 7, MD&A — Consolidated Results
- [30] Item 7, MD&A — Consolidated Results
- [31] Item 7, MD&A — Consolidated Results
- [32] Item 7, MD&A — Consolidated Results
- [33] Item 7, MD&A — Consolidated Results
- [34] Item 7, MD&A — Consolidated Results
- [35] Item 7, MD&A — Consolidated Results
- [36] Item 7, MD&A — Consolidated Results
- [37] Item 7, MD&A — Consolidated Results
- [38] Item 8, Consolidated Statements of Operations
- [39] Item 8, Consolidated Statements of Operations
- [40] Item 8, Consolidated Balance Sheets
- [41] Item 8, Consolidated Balance Sheets
- [42] Item 1A, Risk Factors — Risks Relating to Our Indebtedness
- [43] Item 1A, Risk Factors — Risks Relating to Our Indebtedness
- [44] Item 1A, Risk Factors — Risks Relating to Our Indebtedness
- [45] Item 7, MD&A — Cash Flows
- [46] Item 7, MD&A — Affordable Medicines
- [47] Item 7, MD&A — Net Revenue
- [48] Item 7, MD&A — Net Revenue
- [49] Item 7, MD&A — Specialty
- [50] Item 7, MD&A — Specialty
- [51] Item 7, MD&A — Specialty
- [52] Item 7, MD&A — Specialty
- [53] Item 7, MD&A — Specialty
- [54] Item 7, MD&A — AvKARE
- [55] Item 7, MD&A — AvKARE
- [56] Item 7, MD&A — Affordable Medicines
- [57] Item 7, MD&A — Affordable Medicines
- [58] Item 7, MD&A — Specialty
- [59] Item 7, MD&A — Specialty
- [60] Item 7, MD&A — AvKARE
- [61] Item 7, MD&A — AvKARE
- [62] Item 1, Business — Specialty
- [63] Item 1, Business — Affordable Medicines
- [64] Item 1, Business — Affordable Medicines
- [65] Item 1, Business — Affordable Medicines
- [66] Item 1, Business — Affordable Medicines
- [67] Item 1A, Risk Factors — Failure to successfully implement a new enterprise resource planning system could have a material adverse effect on our business, results of operations and financial condition.
- [68] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [69] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [70] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [71] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [72] Item 7, MD&A — Liquidity and Capital Resources
- [73] Item 7, MD&A — Liquidity and Capital Resources
- [74] Item 1, Business — Affordable Medicines
- [75] Item 1, Business — Affordable Medicines
- [76] Item 1, Business — ApiJect Systems Collaboration Agreement
- [77] Item 1, Business — ApiJect Systems Collaboration Agreement
- [78] Item 1, Business — ApiJect Systems Collaboration Agreement
- [79] Item 1, Business — Affordable Medicines
- [80] Item 1, Business — Affordable Medicines
- [81] Item 1, Business — Affordable Medicines
- [82] Item 1, Business — Metsera, Inc. Collaboration Agreement
- [83] Item 1, Business — Metsera, Inc. Collaboration Agreement
- [84] Item 1, Business — Metsera, Inc. Collaboration Agreement
- [85] Item 1, Business — Metsera, Inc. Collaboration Agreement
- [86] Item 7, MD&A — Inflation
- [87] Item 7, MD&A — Inflation
- [88] Item 7, MD&A — Trade Policy and Tariffs
- [89] Item 7, MD&A — Liquidity and Capital Resources
- [90] Item 7, MD&A — Liquidity and Capital Resources
- [91] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividends
- [92] Item 7, MD&A — Trade Policy and Tariffs
- [93] Item 7, MD&A — Trade Policy and Tariffs
- [94] Item 7, MD&A — Trade Policy and Tariffs
- [95] Item 7, MD&A — Trade Policy and Tariffs
- [96] Item 7, MD&A — Trade Policy and Tariffs
- [97] Item 7, MD&A — Trade Policy and Tariffs
- [98] Item 7, MD&A — One Big Beautiful Bill Act
- [99] Item 7, MD&A — One Big Beautiful Bill Act
- [100] Item 1A, Risk Factors — We face intense competition in the pharmaceutical industry from both brand and generic drug product companies, which could significantly limit our growth and materially adversely affect our financial results.
- [101] Item 1A, Risk Factors — The illegal distribution and sale by third parties of counterfeit versions of our products or of stolen products could have a negative impact on our reputation and a material adverse effect on our business, results of operations and financial condition.
- [102] Item 1A, Risk Factors — Our business is highly dependent on market perceptions of us and the safety and quality of our products.
- [103] Item 1A, Risk Factors — A substantial portion of our total revenues is expected to be derived from sales of a limited number of products.
- [104] Item 1A, Risk Factors — Manufacturing or quality control problems may damage our reputation for quality production, demand costly remedial activities and negatively impact our business, results of operations and financial condition.
- [105] Item 1A, Risk Factors — Our profitability depends on our major customers. If these relationships do not continue as expected, our business, condition (financial and otherwise), prospects and results of operations could materially suffer.
- [106] Item 1A, Risk Factors — Our profitability depends on our major customers. If these relationships do not continue as expected, our business, condition (financial and otherwise), prospects and results of operations could materially suffer.
- [107] Item 1A, Risk Factors — Supply chain disruptions could have a material adverse effect on our business, financial position and results of operations.
- [108] Item 1A, Risk Factors — Changes in trade policy, including the imposition of tariffs may affect our business, results of operations and financial condition.
- [109] Item 1A, Risk Factors — A U.S. government shutdown could adversely impact our regulatory, operational and financial performance.
- [110] Item 1A, Risk Factors — We have a substantial amount of indebtedness, which could adversely affect our financial health.
- [111] Item 1A, Risk Factors — We have a substantial amount of indebtedness, which could adversely affect our financial health.
- [112] Item 1A, Risk Factors — We are required under a tax receivable agreement to make cash payments in respect of certain tax benefits to which we may become entitled, and we expect that the payments we will be required to make will be substantial.
- [113] Item 1A, Risk Factors — We are required under a tax receivable agreement to make cash payments in respect of certain tax benefits to which we may become entitled, and we expect that the payments we will be required to make will be substantial.
- [114] Item 1A, Risk Factors — The Amneal Group owns nearly a majority of our outstanding Class A Common Stock. The interests of the Amneal Group may differ from the interests of our other stockholders.
- [115] Item 1A, Risk Factors — The Amneal Group owns nearly a majority of our outstanding Class A Common Stock. The interests of the Amneal Group may differ from the interests of our other stockholders.
- [116] Item 1A, Risk Factors — Our current operations in, and potential expansion into additional international markets subjects us to increased regulatory oversight both in those international markets and domestically as well as regulatory, economic, social and political uncertainties, which could cause a material adverse effect on our business, financial position and results of operations.
- [117] Item 1A, Risk Factors — Global economic conditions could harm us.
- [118] Item 1A, Risk Factors — Changes in tax laws could have a material adverse effect on our business, results of operations, or financial condition.
- [119] Item 7, MD&A — Specialty
- [120] Item 7, MD&A — Specialty
- [121] Item 1, Business — Affordable Medicines
- [122] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [123] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [124] Item 1A, Risk Factors — Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors which may be beyond our control.
- [125] Item 7, MD&A — Liquidity and Capital Resources
- [126] Item 7, MD&A — Liquidity and Capital Resources
- [127] Item 7, MD&A — Inflation
Analysis on 5/19/2026